Generic Name and Formulations:
Quinupristin/dalfopristin 500mg per vial (as 150mg quinupristin and 350mg dalfopristin); pwd for IV infusion after reconstitution; preservative-free.
Indications for SYNERCID:
Treatment of complicated skin and skin structure infections due to S. aureus (methicillin-susceptible) or S. pyogenes.
Give by IV infusion over 60mins. ≥16yrs: 7.5mg/kg every 12hrs for at least 7 days.
<16yrs: not established; doses of 7.5 mg/kg every 8hrs or 12hrs have been used in a limited number of children under emergency-use conditions (see full labeling).
Hepatic insufficiency. Pregnancy. Nursing mothers.
Avoid concomitant drugs known to prolong the QT interval. Potentiates CYP3A4 substrates (eg, midazolam, nifedipine, cisapride, carbamazepine, vinca alkaloids, taxanes, steroids, NNRTIs, protease inhibitors, statins); monitor esp. those with narrow therapeutic window (eg, cyclosporine, tacrolimus). May affect digoxin.
Inj site reactions, arthralgia, myalgia, GI upset, thrombophlebitis, rash, headache, pruritus; C. difficile-associated diarrhea.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL